Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer

Cancer Genetics

Volumn 204, Issue 10, 2011, Pages 525-535

  Weberpals, Johanne I ^a,b   Koti, Madhuri ^c   Squire, Jeremy A ^c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

BRCA1; EGFR; Epigenetic; Genetics; Ovarian carcinoma; PI3K; Targeted therapeutics

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GANITUMAB; GEFITINIB; GEMCITABINE; LENVATINIB; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PERIFOSINE; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; TEMOZOLOMIDE; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VELIPARIB; XL 147; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; DNA METHYLATION; DNA MODIFICATION; DNA REPAIR; DRUG EFFICACY; DRUG POTENTIATION; EPIGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RISK; GENOMIC INSTABILITY; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OVARY CANCER; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; REVIEW; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; DISEASE COURSE; FEMALE; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM; OVARIAN EPITHELIAL CANCER; OVARY TUMOR; PATHOLOGY; PROGNOSIS;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DNA REPAIR; EPIGENOMICS; FEMALE; GENOMIC INSTABILITY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84859256220     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.09.004     Document Type: Review

References (106)

1. Herzog T.J. Recurrent ovarian cancer: how important is it to treat to disease progression?. Clin Cancer Res 2004, 10:7439-7449.
2. Winter W.E., Maxwell G.L., Tian C., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:3621-3627.
3. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
4. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676-689.
5. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
6. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
7. Helleman J., Smid M., Jansen M.P., et al. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol 2010, 117:170-176.
8. Chao S.Y., Chiang J.H., Huang A.M., et al. An integrative approach to identifying cancer chemoresistance-associated pathways. BMC Med Genomics 2011, 4:23.
9. Swanton C., Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer 2009, 100:1517-1522.
10. Cho K.R., Shih Ie M. Ovarian cancer. Annu Rev Pathol 2009, 4:287-313.
11. Karst A.M., Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010, 932371.
12. Lee K., Tavassoli F., Prat J. Tumors of the breast and female genital organs. Tumors of the ovary and peritoneum 2003, 119-124. IARC Press, Lyon, France. F. Tavasolli, P. Devillee (Eds.).
13. Shih Ie M., Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164:1511-1518.
14. Singer G., Oldt R., Cohen Y., et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003, 95:484-486.
15. Milner B.J., Allan L.A., Eccles D.M., et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993, 53:2128-2132.
16. Bowtell D.D. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010, 10:803-808.
17. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.
18. Sakai W., Swisher E.M., Jacquemont C., et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009, 69:6381-6386.
19. Swisher E.M., Sakai W., Karlan B.Y., et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008, 68:2581-2586.
20. Teoh D.G., Secord A.A. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 2010, 18:31-43.
21. Gadducci A., Cosio S., Fanucchi A., et al. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol 2004, 93:131-136.
22. Rosen D.G., Wang L., Atkinson J.N., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005, 99:267-277.
23. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
24. Tan D.S., Rothermundt C., Thomas K., et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008, 26:5530-5536.
25. Matloff E.T. The breast surgeon's role in BRCA1 and BRCA2 testing. Am J Surg 2000, 180:294-298.
26. Roa B.B., Boyd A.A., Volcik K., et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996, 14:185-187.
27. Cornelis R.S., Neuhausen S.L., Johansson O., et al. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer 1995, 13:203-210.
28. Scully R., Chen J., Plug A., et al. Association of BRCA1 with RAD51 in mitotic and meiotic cells. Cell 1997, 88:265-275.
29. Xu X., Weaver Z., Linke S.P., et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Molecular Cell 1999, 3:389-395.
30. Yu V.P., Koehler M., Steinlein C., et al. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev 2000, 14:1400-1406.
31. Albertson D.G., Collins C., McCormick F., et al. Chromosome aberrations in solid tumors. Nat Genet 2003, 34:369-376.
32. Schreiber V., Dantzer F., Ame J.C., et al. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006, 7:517-528.
33. Pal T., Permuth-Wey J., Betts J.A., et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005, 104:2807-2816.
34. Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
35. Jazaeri A.A., Yee C.J., Sotiriou C., et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002, 94:990-1000.
36. Rice J.C., Massey-Brown K.S., Futscher B.W. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998, 17:1807-1812.
37. Sheng Q., Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer 2011, 104:1241-1245.
38. Wilcox C.B., Baysal B.E., Gallion H.H., et al. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genetics Cytogenetics 2005, 159:114-122.
39. Thrall M., Gallion H.H., Kryscio R., et al. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2006, 16(suppl 1):166-171.
40. Weberpals J.I., Tu D., Squire J.A., et al. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol 2011, 22:2403-2410.
41. Swisher E.M., Gonzalez R.M., Taniguchi T., et al. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 2009, 8:48.
42. Rottenberg S., Nygren A.O., Pajic M., et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:12117-12122.
43. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
44. Thomas H.D., Calabrese C.R., Batey M.A., et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007, 6:945-956.
45. Zander S.A., Kersbergen A., van der Burg E., et al. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 2010, 70:1700-1710.
46. Ledermann J.A., Harter P., Gourley C., et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). 2011 ASCO Annual Meeting. J Clin Oncol 2011, 29(suppl). abstr 5003.
47. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
48. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
49. Meindl A., Hellebrand H., Wiek C., et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010, 42:410-414.
50. Kolasa I.K., Rembiszewska A., Felisiak A., et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 2009, 8:21-26.
51. McCabe N., Turner N.C., Lord C.J., et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006, 66:8109-8115.
52. Turner N.C., Lord C.J., Iorns E., et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. Embo J 2008, 27:1368-1377.
53. Konstantinopoulos P.A., Spentzos D., Karlan B.Y., et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010, 28:3555-3561.
54. Cass I., Baldwin R.L., Varkey T., et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97:2187-2195.
55. Weberpals J., Garbuio K., O'Brien A., et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 2009, 124:806-815.
56. McShane L.M., Altman D.G., Sauerbrei W., et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast cancer research and treatment 2006, 100:229-235.
57. Chalhoub N., Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009, 4:127-150.
58. Zhang S., Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010, 16:4325-4330.
59. Astanehe A., Arenillas D., Wasserman W.W., et al. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci 2008, 121:664-674.
60. Roh M.H., Yassin Y., Miron A., et al. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol 2010, 23:1316-1324.
61. Huang J., Zhang L., Greshock J., et al. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer 2011, 50:606-618.
62. Tanaka Y., Terai Y., Tanabe A., et al. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther 2011, 11:50-57.
63. Espinosa I., Catasus L., Canet B., et al. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Mod Pathol 2011, 24:846-854.
64. Materna V., Surowiak P., Kaplenko I., et al. Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients. Virchows Arch 2007, 450:187-194.
65. Kleinberg L., Dong H.P., Holth A., et al. Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol 2009, 40:795-806.
66. Mabuchi S., Altomare D.A., Cheung M., et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007, 13:4261-4270.
67. Rho S.B., Kim B.R., Kang S. A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol 2011, 120:121-127.
68. Karam A.K., Santiskulvong C., Fekete M., et al. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken) 2010, 67:535-544.
69. Janku F., Tsimberidou A.M., Garrido-Laguna I., et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011, 10:558-565.
70. Campbell I.G., Russell S.E., Choong D.Y., et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer research 2004, 64:7678-7681.
71. Wang Y., Helland A., Holm R., et al. PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 2005, 25:322.
72. Ohta T., Isobe M., Takahashi T., et al. The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome. Anticancer research 2009, 29:4639-4647.
73. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61(suppl 2):1-13.
74. Moscatello D.K., Montgomery R.B., Sundareshan P., et al. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 1996, 13:85-96.
75. Pautier P., Joly F., Kerbrat P., et al. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol 2010, 116:157-162.
76. Schilder R.J., Sill M.W., Chen X., et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005, 11:5539-5548.
77. Posadas E.M., Liel M.S., Kwitkowski V., et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007, 109:1323-1330.
78. Siwak D.R., Carey M., Hennessy B.T., et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010, 568938.
79. Blank S.V., Christos P., Curtin J.P., et al. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol 2010, 119:451-456.
80. Annunziata C.M., Walker A.J., Minasian L., et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 2010, 16:664-672.
81. Palayekar M.J., Herzog T.J. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int J Gynecol Cancer 2008, 18:879-890.
82. Servidei T., Riccardi A., Mozzetti S., et al. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. Int Journal Cancer 2008, 123:2939-2949.
83. Sergina N.V., Rausch M., Wang D., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
84. Gordon M.Y., Levicar N., Pai M., et al. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells 2006, 24:1822-1830.
85. Makhija S., Amler L.C., Glenn D., et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010, 28:1215-1223.
86. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159.
87. Chou J.L., Su H.Y., Chen L.Y., et al. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest 2010, 90:414-425.
88. Li M., Balch C., Montgomery J.S., et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009, 2:34.
89. Dai W., Teodoridis J.M., Zeller C., et al. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 2011, 17:4052-4062.
90. Matei D.E., Nephew K.P. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecologic oncology 2010, 116:195-201.
91. Weisenberger D.J., Campan M., Long T.I., et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005, 33:6823-6836.
92. Strathdee G., Vass J.K., Oien K.A., et al. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol 2005, 97:898-903.
93. Bast R., Iyer B., Hu W., et al. A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer. J Clin Oncol 2008, 26(suppl).
94. Sharma S.V., Lee D.Y., Li B., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
95. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
96. Boyerinas B., Park S.M., Murmann A.E., et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of MDR1. Int J Cancer 2011, [Epub ahead of print].
97. Sorrentino A., Liu C.G., Addario A., et al. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008, 111:478-486.
98. Iorio M.V., Visone R., Di Leva G., et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67:8699-8707.
99. Nam E.J., Yoon H., Kim S.W., et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008, 14:2690-2695.
100. Gallagher M.F., Flavin R.J., Elbaruni S.A., et al. Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients. J Ovarian Res 2009, 2:19.
101. Wyman S.K., Parkin R.K., Mitchell P.S., et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009, 4:e5311.
102. van Jaarsveld M.T., Helleman J., Berns E.M., et al. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010, 42:1282-1290.
103. Lee C.H., Subramanian S., Beck A.H., et al. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One 2009, 4:e7314.
104. Shen J., Ambrosone C.B., DiCioccio R.A., et al. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008, 29:1963-1966.
105. Yang H., Kong W., He L., et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008, 68:425-433.
106. Tan D.S., Thomas G.V., Garrett M.D., et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009, 15:406-420.